The predictive value of lncRNA LAMTOR5-AS1 in the recurrence after endoscopic submucosal dissection for early gastric cancer

Abstract

Listen

Translate article

Abstract Introduction Endoscopic submucosal dissection (ESD) is effective and widely used in the clinical treatment of early gastric cancer. This study revealed the predictive value of abnormal expression of lncRNA LAMTOR5-AS1 (LAMTOR5-AS1) in the recurrence of early gastric cancer patients after ESD and preliminarily explored the molecular mechanism of LAMTOR5-AS1 in gastric cancer. Materials and Methods The level of LAMTOR5-AS1 in the gastric cancer patients (n = 130) and healthy individuals (n = 130) was assessed using RT-qPCR. The ROC curve was established to characterize the diagnostic efficacy of LAMTOR5-AS1 in gastric cancer and recurrence after ESD treatment. Logistic regression analysis was employed to assess the risk factors associated with postoperative recurrence in gastric cancer patients. The regulatory effect of LAMTOR5-AS1 on gastric cancer cells was verified by CCK-8 and Transwell assay. Results LAMTOR5-AS1 was upregulated in gastric cancer tissues, and LAMTOR5-AS1 expression in the recurrence group was also enhanced. The area under the curve (AUC) of LAMTOR5-AS1 expression in differentiating gastric cancer patients from healthy controls was 0.9076, while the AUC of LAMTOR5-AS1 expression in predicting recurrence after ESD for early gastric cancer was 0.8147. LAMTOR5-AS1 was confirmed to be an independent risk factor for recurrence after ESD. Silencing of LAMTOR5-AS1 inhibited the biological activity of gastric cancer cells, which was reversed by miR-331-3p inhibitor. Conclusions LAMTOR5-AS1 was overexpressed in the recurrence group after ESD, which may be a predictive biomarker in the recurrence of EGC for early gastric cancer patients.